Lumbar Posterolateral Fusion Using Heparin-Conjugated Fibrin for Sustained Delivery of Bone Morphogenic Protein-2 in a Rabbit Model

Artificial Organs

Volumn 36, Issue 7, 2012, Pages 629-634

  Koo, Ki Hyoung ^a   Yeo, Do Hyun ^a   Ahn, Jung Min ^a   Kim, Byung Soo ^b   Kim, Chang Sung ^c   Im, Gun Il ^a  

^a Dongguk University Ilsan Hospital   (South Korea)

^b Seoul National University   (South Korea)

^c Yonsei University College of Dentistry   (South Korea)

Author keywords

Bone morphogenic protein 2; Drug delivery system; Heparin conjugated fibrin; Long term delivery system; Spine fusion

Indexed keywords

BONE; COLLAGEN; COMPUTERIZED TOMOGRAPHY; CONTROLLED DRUG DELIVERY; TARGETED DRUG DELIVERY; TENSILE STRENGTH; TENSILE TESTING;

BONE MORPHOGENIC PROTEIN; BONE MORPHOGENIC PROTEIN-2; COLLAGEN SPONGE; DELIVERY SYSTEMS; DRUG-DELIVERY SYSTEMS; HEPARIN-CONJUGATED FIBRIN; LONG-TERM DELIVERY SYSTEM; LUMBAR SPINES; RABBIT MODELS; SPINE FUSION;

POLYSACCHARIDES;

COLLAGEN SPONGE; DRUG CARRIER; FIBRIN; HEPARIN; HEPARIN CONJUGATED FIBRIN; RECOMBINANT BONE MORPHOGENETIC PROTEIN 2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BIOMECHANICS; BONE REGENERATION; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; GEL; LUMBAR POSTEROLATERAL FUSION; NONHUMAN; PALPATION; PRIORITY JOURNAL; RABBIT; RANDOMIZED CONTROLLED TRIAL; SPINE FUSION; SPINE RADIOGRAPHY; SUSTAINED DRUG RELEASE; TENSILE STRENGTH;

ANIMALIA; ORYCTOLAGUS CUNICULUS;

EID: 84863504175     PISSN: 0160564X     EISSN: 15251594     Source Type: Journal    
DOI: 10.1111/j.1525-1594.2012.01444.x     Document Type: Article

References (23)

1. Boden SD. Overview of the biology of lumbar spine fusion and principles for selecting a bone graft substitute. Spine 2002;27:S26-31.
2. Boden SD. The biology of posterolateral lumbar spine fusion. Orthop Clin North Am 1998;29:609-19.
3. Brandoff JF, Silber JS, Vaccaro AR. Contemporary alternatives to synthetic bone grafts for spine surgery. Am J Orthop 2008;37:410-4.
4. Bets RR. Limitations of autograft and allograft: new synthetic solutions. Orthopaedics 2002;25:S561-70.
5. Mont MA, Ragland PS, Biggins B, etal. Use of bone morphogenetic proteins for musculoskeletal applications. An overview. J Bone Joint Surg Am 2004;86-A(Suppl. 2):41-55.
6. Zlotolow DA, Vaccaro AR, Salamon ML, Albert TJ. The role of human bone morphogenetic proteins in spinal fusion. J Am Acad Orthop Surg 2000;8:3-9.
7. McKay B, Sandhu HS. Use of recombinant human bone morphogenetic protein-2 in spinal fusion applications. Spine 2002;27(Suppl. 1):S66-85.
8. Hsu WK, Wang JC. The use of bone morphogenetic protein in spine fusion. Spine J 2008;8:419-25.
9. Vaccaro AR, Whang PG, Patel T, etal. The safety and efficacy of OP-1 (rhBMP-7) as a replacement for iliac crest autograft for posterolateral lumbar arthrodesis: minimum 4-year follow-up of a pilot study. Spine J 2008;8:457-65.
10. White AP, Vaccaro AR, Hall JA, Whang PG, Friel BC, McKee MD. Clinical applications of BMP-7/OP-1 in fractures, nonunions and spinal fusion. Int Orthop 2007;31:735-41.
11. Liao SS, Guan K, Cui FZ, Shi SS, Sun TS. Lumbar spinal fusion with a mineralized collagen matrix and rhBMP-2 in a rabbit model. Spine 2003;28:1954-60.
12. Hwang CJ, Vaccaro AR, Lawrence JP, etal. Immunogenicity of bone morphogenetic proteins. J Neurosurg Spine 2009;10:443-51.
13. Carragee EJ, Hurwitz EL, Weiner BK. A critical review of recombinant human bone morphogenetic protein-2 trials in spinal surgery: emerging safety concerns and lessons learned. Spine J 2011;11:471-91.
14. Patel VV, Zhao L, Wong P, etal. Controlling bone morphogenetic protein diffusion and bone morphogenetic protein-stimulated bone growth using fibrin glue. Spine 2007;31:1201-6.
15. La WG, Kang SW, Yang HS, etal. The efficacy of bone morphogenetic protein-2 depends on its mode of delivery. Artif Organs 2010;34:1150-3.
16. Yamamoto M, Takahashi Y, Tabata Y. Enhanced bone regeneration at a segmental bone defect by controlled release of bone morphogenetic protein-2 from a biodegradable hydrogel. Tissue Eng 2006;12:1305-11.
17. Takahashi Y, Yamamoto M, Tabata Y. Enhanced osteoinduction by controlled release of bone morphogenetic protein-2 from biodegradable sponge composed of gelatin and beta-tricalcium phosphate. Biomaterials 2005;26:4856-65.
18. Yang HS, La WG, Bhang SH, Jeon JY, Lee JH, Kim BS. Heparin-conjugated fibrin as an injectable system for sustained delivery of bone morphogenetic protein-2. Tissue Eng Part A 2010;16:1225-33.
19. Jeon O, Song SJ, Yang HS, etal. Long-term delivery enhances in vivo osteogenic efficacy of bone morphogenetic protein-2 compared to short-term delivery. Biochem Biophys Res Commun 2008;369:774-80.
20. Feiertag MA, Boden SD, Schimandle JH, Norman JT. A rabbit model for nonunion of lumbar intertransverse fusion. Spine 1996;21:27-31.
21. Zhao B, Katagiri T, Toyoda H, etal. Heparin potentiates the in vivo ectopic bone formation induced by bone morphogenetic protein-2. J Biol Chem 2006;281:23246-53.
22. Yee AJ, Bae HW, Friess D, Robbin M, Johnstone B, Yoo JU. Accuracy and interobserver agreement for determinations of rabbit posterolateral spinal fusion. Spine 2004;29:1308-13.
23. Shields LB, Raque GH, Glassman SD, etal. Adverse effects associated with high-dose recombinant human bone morphogenetic protein-2 use in anterior cervical spine fusion. Spine 2006;31:542-7.